Aprea Therapeutics, Inc.
APRE · XNASCIK 1781983fmd_04PHGD8571KE6508WBP4J065TGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 35 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Research and development | 13 | 14 | 21 | 38 | 24 | 16 | 8 | 9 | 7 |
| Total operating expenses | 16 | 16 | 30 | 53 | 37 | 113 | 16 | 16 | 14 |
| Operating income | – | – | – | – | (37) | (113) | (15) | (14) | (13) |
| Other non-operating income (expense) | 1 | 1 | 1 | (1) | 0 | 1 | 1 | 1 | 1 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (15) | (16) | (28) | (53) | (37) | (113) | (14) | (13) | (13) |